Immunome, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMNM research report →
Companyimmunome.com
Immunome, Inc. , a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system.
- CEO
- Clay Siegall
- IPO
- 2020
- Employees
- 131
- HQ
- Bothell, PA, US
Price Chart
Valuation
- Market Cap
- $2.06B
- P/E
- -10.85
- P/S
- 512.62
- P/B
- 4.14
- EV/EBITDA
- -6.34
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -1161.92%
- Op Margin
- -5947.90%
- Net Margin
- -5593.85%
- ROE
- -51.15%
- ROIC
- -40.31%
Growth & Income
- Revenue
- $6.94M · -23.23%
- Net Income
- $-212,394,000 · 27.50%
- EPS
- $-2.43 · 51.40%
- Op Income
- $-214,113,000
- FCF YoY
- -22.09%
Performance & Tape
- 52W High
- $27.65
- 52W Low
- $7.83
- 50D MA
- $21.97
- 200D MA
- $18.30
- Beta
- 2.12
- Avg Volume
- 1.15M
Get TickerSpark's AI analysis on IMNM
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 15, 26 | BIENAIME JEAN JACQUES | buy | 5,000 |
| Apr 2, 26 | Higgins Jack | sell | 9,438 |
| Apr 2, 26 | Rosett Max | other | 39,713 |
| Apr 2, 26 | Rosett Max | other | 31,848 |
| Apr 2, 26 | Rosett Max | other | 31,848 |
| Apr 2, 26 | Rosett Max | sell | 63,656 |
| Apr 2, 26 | Rosett Max | sell | 1,344 |
| Apr 2, 26 | Rosett Max | other | 39,713 |
| Mar 30, 26 | Higgins Jack | other | 6,291 |
| Mar 27, 26 | SIEGALL CLAY B | buy | 25,450 |
Our IMNM Coverage
We haven't published any research on IMNM yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IMNM Report →